Mizuho Downgrades Arcutis Biotherapeutics to Neutral, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear has downgraded Arcutis Biotherapeutics (NASDAQ:ARQT) from Buy to Neutral and lowered the price target from $57 to $4.

October 26, 2023 | 6:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arcutis Biotherapeutics has been downgraded by Mizuho from Buy to Neutral, with a significant reduction in price target from $57 to $4.
The downgrade from Buy to Neutral by Mizuho indicates a less optimistic outlook for Arcutis Biotherapeutics. The significant reduction in price target from $57 to $4 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in its stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100